BRPI0822420A2 - COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A DISEASE IN AN ANIMAL AND TO TREAT A PATIENT WHO GOES THROUGH A TAREPIA. - Google Patents

COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A DISEASE IN AN ANIMAL AND TO TREAT A PATIENT WHO GOES THROUGH A TAREPIA.

Info

Publication number
BRPI0822420A2
BRPI0822420A2 BRPI0822420-0A2A BRPI0822420A BRPI0822420A2 BR PI0822420 A2 BRPI0822420 A2 BR PI0822420A2 BR PI0822420 A BRPI0822420 A BR PI0822420A BR PI0822420 A2 BRPI0822420 A2 BR PI0822420A2
Authority
BR
Brazil
Prior art keywords
treat
tarepia
animal
disease
goes
Prior art date
Application number
BRPI0822420-0A2A
Other languages
Portuguese (pt)
Inventor
John O Link
Criag J Mossman
Jie Liu
Soon Hyung Woo
Original Assignee
Virobay Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virobay Inc filed Critical Virobay Inc
Publication of BRPI0822420A2 publication Critical patent/BRPI0822420A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0822420-0A2A 2008-04-01 2008-04-01 COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A DISEASE IN AN ANIMAL AND TO TREAT A PATIENT WHO GOES THROUGH A TAREPIA. BRPI0822420A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/059025 WO2009123623A1 (en) 2008-04-01 2008-04-01 Di-fluoro containing compounds as cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0822420A2 true BRPI0822420A2 (en) 2014-10-07

Family

ID=41135860

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822420-0A2A BRPI0822420A2 (en) 2008-04-01 2008-04-01 COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A DISEASE IN AN ANIMAL AND TO TREAT A PATIENT WHO GOES THROUGH A TAREPIA.

Country Status (5)

Country Link
EP (1) EP2262370A4 (en)
JP (1) JP5497732B2 (en)
CN (1) CN102014635B (en)
BR (1) BRPI0822420A2 (en)
WO (1) WO2009123623A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012174552A2 (en) * 2011-06-17 2012-12-20 Virobay, Inc. Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375134B2 (en) * 2002-03-05 2008-05-20 Axys Pharmaceuticals, Inc. Cathepsin cysteine protease inhibitors
CN1842515A (en) * 2003-08-27 2006-10-04 默克弗罗斯特加拿大有限公司 Cathepsin inhibitors
DK1663958T3 (en) * 2003-09-18 2015-04-07 Virobay Inc HALOAL COOLING COMPOUNDS AS CYSTEIN PROTEASE INHIBITORS
EP1682524A1 (en) * 2003-10-24 2006-07-26 Aventis Pharmaceuticals, Inc. Novel keto-oxadiazole derivatives as cathepsin inhibitors
EP2079683B1 (en) * 2006-10-04 2015-01-21 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors

Also Published As

Publication number Publication date
CN102014635A (en) 2011-04-13
WO2009123623A1 (en) 2009-10-08
JP2011521893A (en) 2011-07-28
EP2262370A1 (en) 2010-12-22
CN102014635B (en) 2015-12-16
JP5497732B2 (en) 2014-05-21
EP2262370A4 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
BRPI1004899A2 (en) compound, pharmaceutical composition, method for treating a pi3k-related disease or disorder in an individual in need thereof, method for treating a mtor-mediated disease, method for treating both pi3k and hdac-mediated diseases
BRPI0915382A2 (en) compound, pharmaceutical composition, and method for treating a disease or disorder.
BRPI0908503A2 (en) particle less than 2mm in diameter, and composition for tissue treatment
BRPI0814503A2 (en) compound, use of a compound, methods for producing an antiproliferative effect in a warm-blooded animal, and for treating a disease, and, pharmaceutical composition
BRPI0812851A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATMENT OF A DISEASE AND CONDITION IN AN INDIVIDUAL, PROCESS FOR PREPARING A COMPOUND, AND USE OF A COMPOUND
BRPI0813725A2 (en) METHODS AND COMPOSITIONS FOR DISEASE TREATMENT
BRPI0822750A2 (en) Oral care implement and method for marketing an oral care implement and faceplate.
BRPI0914902A2 (en) pharmaceutical composition and method for treating parkinson's disease
BR112012004333A2 (en) compound, pharmaceutical composition, and method for treating or preventing a disease or disorder.
BR112015003397A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient.
BRPI0819690A2 (en) METHOD TO TREAT A PATIENT SUFFERING FROM FATTY LIVER DISEASE
BR112012005398A2 (en) implantable device and method for administering lidocaine to a patient's bladder
BRPI0819642A2 (en) Method for forming a denture for a patient in a single visit, and, denture
BRPI0906453A2 (en) Oral Care Composition and Method for Improving Oral Health
MX2018013333A (en) Therapeutic nuclease compositions and methods.
BRPI0816097A2 (en) pharmaceutical composition, method for treating erythema in a patient with rosacea, and, use of a composition.
BR112015003332A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient
BR112015003398A2 (en) compound, pharmaceutical composition, use of the compound and method for treating a rorgammat-mediated disease or condition in a patient
BRPI1009343A2 (en) method performed by hardware running software, and non-temporary computer readable media
BRPI1012066A2 (en) oral care composition, and methods for preparing the oral care composition and for administering a zinc compound to an animal or human individual in need thereof
BRPI0814688A2 (en) compound, use of a compound, methods for producing an antiproliferative effect on a warm-blooded animal, and for treating disease, and, pharmaceutical composition
AR065392A1 (en) METHODS FOR TREATMENT BY INHALATION OF A DISEASE OR RESPIRATORY STATE
BR112012003464A2 (en) compound, pharmaceutical composition, uses of a pharmaceutical composition and a compound, and method for treating a disease or disorder. "
HUE050319T2 (en) Compositions and methods for treating alcohol-related disorders, pain and other diseases
BRPI0912539A2 (en) compound, pharmaceutical composition, method for treating a disease, and use of the compound.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)